keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/29451078/oncologists-perceptions-of-drug-affordability-using-nccn-evidence-blocks-results-from-a-national-survey
#1
Bijal Shah-Manek, William Wong, Arliene Ravelo, Marco DiBonaventura
BACKGROUND: The increasing prevalence of cancer coupled with approvals of new drugs and technologies used in therapy have brought increased scrutiny to the cost and value of treatments in oncology. To address the rising concern about oncology drug costs, several organizations have developed value frameworks to help assess the value of oncology regimens. The objective of this study was to assess oncologists' perceptions, awareness, and knowledge of all oncology value frameworks in the United States and to understand oncologists' perceptions of affordability in the context of National Comprehensive Cancer Network (NCCN) Evidence Blocks...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29449897/atezolizumab-feasible-second-line-therapy-for-patients-with-non-small-cell-lung-cancer-a-review-of-efficacy-safety-and-place-in-therapy
#2
REVIEW
Fanny Jean, Pascale Tomasini, Fabrice Barlesi
Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29443651/american-society-of-clinical-oncology-statement-biosimilars-in-oncology
#3
Gary H Lyman, Edward Balaban, Michael Diaz, Andrea Ferris, Anne Tsao, Emile Voest, Robin Zon, Michael Francisco, Sybil Green, Shimere Sherwood, R Donald Harvey, Richard L Schilsky
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education...
February 14, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29442540/management-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitor-therapy-american-society-of-clinical-oncology-clinical-practice-guideline
#4
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B Leighl, Jennifer S Mammen, David F McDermott, Aung Naing, Loretta J Nastoupil, Tanyanika Phillips, Laura D Porter, Igor Puzanov, Cristina A Reichner, Bianca D Santomasso, Carole Seigel, Alexander Spira, Maria E Suarez-Almazor, Yinghong Wang, Jeffrey S Weber, Jedd D Wolchok, John A Thompson
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process...
February 14, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29439009/her2-testing-of-gastro-oesophageal-adenocarcinoma-a-commentary-and-guidance-document-from-the-association-of-clinical-pathologists-molecular-pathology-and-diagnostics-committee
#5
REVIEW
Newton A C S Wong, Fernanda Amary, Rachel Butler, Richard Byers, David Gonzalez, Harry R Haynes, Mohammad Ilyas, Manuel Salto-Tellez, Philippe Taniere
The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma...
February 8, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29411148/from-a-patient-advocate-s-perspective-does-cancer-immunotherapy-represent-a-paradigm-shift
#6
REVIEW
Debra L Madden
PURPOSE OF REVIEW: In 2016, the American Society of Clinical Oncology (ASCO) announced immunotherapy as the year's top cancer advance in its "Clinical Cancer Advances 2016: ASCO's Annual Report on Progress Against Cancer." Further, ASCO again named "Immunotherapy 2.0" as the 2017 advance of the year, emphasizing the recent, rapid pace of research into new agents that harness and enhance the innate abilities of the immune system to recognize and fight cancers-and stressing that such agents have extended the lives of many patients with late-stage cancers for which there have been few treatment options...
February 7, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29409108/psychometric-evaluation-and-adaptation-of-the-spine-oncology-study-group-outcomes-questionnaire-to-evaluate-health-related-quality-of-life-in-patients-with-spinal-metastases
#7
Anne L Versteeg, Arjun Sahgal, Laurence D Rhines, Daniel M Sciubba, James M Schuster, Michael H Weber, Peter Pal Varga, Stefano Boriani, Chetan Bettegowda, Michael G Fehlings, Michelle J Clarke, Paul M Arnold, Ziya L Gokaslan, Charles G Fisher
BACKGROUND: The Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ) was developed as the first spine oncology-specific health-related quality of life (HRQOL) measure. This study evaluated the psychometric properties and clinical validity of the SOSGOQ in a diverse cohort of patients with spinal metastases. METHODS: An international, multicenter, prospective observational cohort study including patients with spinal metastases who underwent surgery and/or radiotherapy was conducted by the AOSpine Knowledge Forum Tumor...
February 6, 2018: Cancer
https://www.readbyqxmd.com/read/29406446/comparison-of-different-scoring-systems-in-the-assessment-of-estrogen-receptor-status-for-predicting-prognosis-in-endometrial-cancer
#8
Yue Wang, Xiaolong Ma, Yuxiang Wang, Yan Liu, Congrong Liu
The objective of this article is to compare the effectiveness of various estrogen receptor (ER) scoring systems for predicting prognosis in endometrial cancer (EC). We retrospectively analyzed 195 cases of primary EC with complete follow-up information. Three different methods-the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criterion, histochemistry score (H-score), and Allred scoring system-were used to assess the degree of staining, and comparisons were made to determine which method correlated best with clinical outcomes...
February 5, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29401004/molecular-testing-guideline-for-the-selection-of-patients-with-lung-cancer-for-treatment-with-targeted-tyrosine-kinase-inhibitors-american-society-of-clinical-oncology-endorsement-of-the-college-of-american-pathologists-international-association-for-the-study
#9
Gregory P Kalemkerian, Navneet Narula, Erin B Kennedy, William A Biermann, Jessica Donington, Natasha B Leighl, Madelyn Lew, James Pantelas, Suresh S Ramalingam, Martin Reck, Anjali Saqi, Michael Simoff, Navneet Singh, Baskaran Sundaram
Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations...
February 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29395315/patterns-of-palliative-care-referral-in-ovarian-cancer-a-single-institution-5%C3%A2-year-retrospective-analysis
#10
Roni Nitecki, Elisabeth J Diver, Mihir M Kamdar, David M Boruta, Marcela C Del Carmen, Rachel M Clark, Annekathryn Goodman, John O Schorge, Whitfield B Growdon
BACKGROUND: The American Society of Clinical Oncology recommends that patients with advanced cancer receive dedicated palliative care services early in their disease course. This investigation serves to understand how palliative care services are utilized for ovarian cancer patients in a tertiary referral center. METHODS: We conducted a retrospective review of women treated for ovarian cancer at our institution from 2010 through 2015. Clinical variables included presence and timing of palliative care referral...
January 27, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29393967/inpatient-utilization-and-disparities-the-last-year-of-life-of-adolescent-and-young-adult-oncology-patients-in-california
#11
Emily E Johnston, Elysia Alvarez, Olga Saynina, Lee M Sanders, Smita Bhatia, Lisa J Chamberlain
BACKGROUND: Studies of adolescent and young adult (AYA) oncology end-of-life care utilization are critical because cancer is the leading cause of nonaccidental AYA death and end-of-life care contributes significantly to health care expenditures. This study was designed to determine the quantity of and disparities in inpatient utilization in the last year of life of AYAs with cancer. METHODS: The California Office of Statewide Health Planning and Development administrative discharge database, linked to death certificates, was used to perform a population-based analysis of cancer patients aged 15 to 39 years who died in 2000-2011...
February 2, 2018: Cancer
https://www.readbyqxmd.com/read/29391418/hypomagnesemia-and-clinical-benefits-of-anti-egfr-monoclonal-antibodies-in-wild-type-kras-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#12
Meng-Chiao Hsieh, Chun-Feng Wu, Chun-Wei Chen, Chung-Sheng Shi, Wen-Shih Huang, Feng-Che Kuan
Hypomagnesemia is a recognized side-effect of cetuximab- or panitumumab-based chemotherapy for metastatic colorectal cancer (mCRC). The clinical relevance of hypomagnesemia is under debate. Thus, a systematic review and meta-analysis of retrospective studies and randomized clinical trials (RCTs) comparing hypomagnesemia with normal magnesium levels in wild-type KRAS mCRC was performed. One RCT, two retrospective studies, and two American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) conference presentations from phase III RCTs involving 1723 patients were included in this study...
February 1, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29384691/utility-of-alternate-noncentromeric-chromosome-17-reference-probe-for-human-epidermal-growth-factor-receptor-fluorescence-in-situ-hybridization-testing-in-breast-cancer-cases
#13
Trupti Pai, Tanuja Shet, Asawari Patil, Omshree Shetty, Angad Singh, Sangeeta B Desai
CONTEXT: - PathVysion-a US Food and Drug Administration-approved dual-probe human epidermal growth factor receptor ( HER2) fluorescence in situ hybridization (FISH) assay-provides the HER2: CEP17 ratio, a centromeric enumeration probe ratio for determining HER2 status in breast cancers. However, pericentromeric amplifications might then skew the HER2: CEP17 ratio, underestimating the HER2 status, which calls into question the use of CEP17 as the reference probe. OBJECTIVE: - To analyze the utility of a noncentromeric chromosome 17 reference locus ( D17S122) to assess HER2 gene status in cases showing "nonclassical" FISH patterns with the CEP17 probe...
January 31, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29380678/clinical-cancer-advances-2018-annual-report-on-progress-against-cancer-from-the-american-society-of-clinical-oncology
#14
John Heymach, Lada Krilov, Anthony Alberg, Nancy Baxter, Susan Marina Chang, Ryan Corcoran, William Dale, Angela DeMichele, Catherine S Magid Diefenbach, Andrew S Epstein, Maura L Gillison, David L Graham, Joshua Jones, Andrew H Ko, Ana Maria Lopez, Robert G Maki, Carlos Rodriguez-Galindo, Richard L Schilsky, Mario Sznol, Shannon Neville Westin, Harold Burstein
No abstract text is available yet for this article.
January 30, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29375032/incorporating-radiation-oncology-into-immunotherapy-proceedings-from-the-astro-sitc-nci-immunotherapy-workshop
#15
Ariel E Marciscano, Joshua M Walker, Heather M McGee, Michelle M Kim, Charles A Kunos, Arta M Monjazeb, Stephen L Shiao, Phuoc T Tran, Mansoor M Ahmed
Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses...
January 29, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29369859/newscap-the-american-society-of-clinical-oncology-asco-calls-for-interventions-to-reduce-cancer-deaths-from-alcohol
#16
(no author information available yet)
No abstract text is available yet for this article.
February 2018: American Journal of Nursing
https://www.readbyqxmd.com/read/29358884/short-and-long-term-outcomes-following-laparoscopic-vs-open-surgery-for-pathological-t4-colorectal-cancer-10-years-of-experience-in-a-single-center
#17
Zi-Feng Yang, De-Qing Wu, Jun-Jiang Wang, Ze-Jian Lv, Yong Li
AIM: To evaluate the short-term and long-term outcomes following laparoscopic vs open surgery for pathological T4 (pT4) colorectal cancer. METHODS: We retrospectively analyzed the short- and long-term outcomes of proven pT4 colorectal cancer patients who underwent complete resection by laparoscopic or open surgery from 2006 to 2015 at Guangdong General Hospital. RESULTS: A total of 211 pT4 colorectal cancer patients were included in this analysis, including 101 cases in the laparoscopy (LAP) group and 110 cases in the open surgery (OPEN) group [including 15 (12...
January 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29346042/treatment-of-malignant-pleural-mesothelioma-american-society-of-clinical-oncology-clinical-practice-guideline
#18
Hedy L Kindler, Nofisat Ismaila, Samuel G Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner, Valerie Rusch, Daniel Sterman, Anish Thomas, Raffit Hassan
Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life...
January 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29341831/role-of-bone-modifying-agents-in-multiple-myeloma-american-society-of-clinical-oncology-clinical-practice-guideline-update
#19
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, Susan Halabi, Sundar Jagannath, Mohammed S Ogaily, Jim Omel, Noopur Raje, G David Roodman, Gary C Yee, Robert A Kyle
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29340530/the-use-of-biosimilar-medicines-in-oncology-position-statement-of-the-brazilian-society-of-clinical-oncology-sboc
#20
G S Fernandes, C Sternberg, G Lopes, R Chammas, M A C Gifoni, R A Gil, D V Araujo
A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, but it does allow the replication of similar molecules with the same activity. As biosimilars are about to be introduced in oncology practice, these must be evaluated through evidence-based medicine...
January 11, 2018: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"